Abrinica, Clyde .
HRN: 27-22-75 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/04/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/04/2025
06/10/2025
IV
40mg
Q12
PCAP D
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes